Arvinas, Inc. (ARVN)
NASDAQ • Healthcare
Last close at September 16, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Arvinas, Inc. keeps $68 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 49 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arvinas’ second fiscal quarter of 2026 featured negative operating cash flow, with operating cash flow at -$48.3 million, as it continued to fund development of its targeted protein degradation programs; the company reported the results on August 4, 2026. Looking ahead, next-period consensus calls for EPS of -$0.87 on revenue of $16.8 million.
About Arvinas, Inc.
Arvinas, Inc. is a NASDAQ-listed biotechnology company that develops protein-degradation medicines aimed at eliminating disease-causing proteins. Its business centers on identifying, advancing, and marketing these therapies, and it generated $262.6 million of revenue in FY2025 through a model built around partnered drug development and clinical-stage candidates.
Today's Snapshot
ARVN closed 1.2% below yesterday's close, while its sector was flat. Arvinas outlined its drug pipeline and spending plans at an investor conference hosted by Morgan Stanley.
Trading Volume
Below 10d avg (911.5K)
726.1K
vs S&P 500 Today
Underperforming Market
-0.63%
Updated: September 16, 2026 at 20:06 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$8.65 - $9.88Sell
- RSI (14)35.34Neutral
- Stochastic %K (14, 3, 3)6.51Buy
- MACD Level (12, 26)-0.13Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.